< IP News

NAFTA Arbitration Tribunal Issues Ruling On Eli Lilly Challenge Against Canada

NAFTA’s arbitration tribunal has issued a decision in favour of the Government of Canada in response to a challenge against it by Eli Lilly and Company under the dispute settlement provisions of NAFTA Chapter 11. Eli Lilly had alleged that the interpretation of the term “useful” in Canada’s Patent Act by the Canadian courts in invalidating Eli Lilly’s Zyprexa and Strattera patents violated Canada’s obligations under NAFTA on the basis that such interpretation was arbitrary and discriminatory. The tribunal agreed with Canada’s position that Eli Lilly’s claims could not form the basis for a challenge under NAFTA Chapter 11 and in any event were without merit.

Read the NAFTA Arbitration Tribunal’s decision in full.


Information made available on this website in any form is for information purposes only. It is not, and should not be taken as legal advice. You should not rely on, or take or fail to take any action, based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Oyen Wiggs Green & Mutala LLP professionals will be pleased to discuss resolutions to specific legal concerns you may have.

Related Expertise

Related Industries